Any point can be considered low -- even after massive gains -- provided there is plenty of upside left. That brings us to ...

Discover Axsome Therapeutics (NASDAQ:AXSM), a pioneering biopharmaceutical company dedicated to creating innovative ...

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Genmab (GMAB – Research Report), with a price target of $25.00. The company’s shares ...